NHE3-binding compounds and methods for inhibiting phosphate transport

Patent metadata

Field	Value
Publication number	US-10272079-B2
Application number	US-201414783983-A
Country	US
Kind code	B2
Filing date	Apr 10, 2014
Priority date	Apr 12, 2013
Publication date	Apr 30, 2019
Grant date	Apr 30, 2019

Abstract

Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.

First claim

The invention claimed is:

1. A method for inhibiting phosphate uptake in the gastrointestinal tract of a patient in need of phosphate lowering, comprising enterally administering to the patient an effective amount of the compound

2. The method of claim 1 , wherein the pharmaceutically acceptable salt is

3. A method for treating hyperphosphatemia in a subject in need thereof comprising administering to the subject an effective amount of the compound

or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 , wherein the pharmaceutically acceptable salt is

5. The method of claim 1 , further comprising administering an additional biologically active agent.

6. The method of claim 5 , wherein the additional biologically active agent is a phosphate binder.

7. The method of claim 6 , wherein the phosphate binder is selected from the group consisting of sevelamer, sevelamer carbonate, sevelamer hydrochloride, lanthanum carbonate, calcium carbonate, calcium acetate, magnesium carbonate, MCI-196, ferric citrate, magnesium iron hydroxycarbonate, aluminum hydroxide, APS1585, SBR-759, and PA-21.

8. The method of claim 6 , wherein the phosphate binder is selected from the group consisting of sevelamer carbonate, lanthanum carbonate, calcium carbonate, calcium acetate, calcium acetate/magnesium carbonate, ferric citrate, magnesium iron hydroxycarbonate, and aluminum hydroxide.

9. The method of claim 6 , wherein the phosphate binder is sevelamer, sevelamer carbonate, or sevelamer hydrochloride.

10. The method of claim 3 , further comprising administering an additional biologically active agent.

11. The method of claim 10 , wherein the additional biologically active agent is a phosphate binder.

12. The method of claim 11 , wherein the phosphate binder is selected from the group consisting of sevelamer, sevelamer carbonate, sevelamer hydrochloride, lanthanum carbonate, calcium carbonate, calcium acetate, magnesium carbonate, MCI-196, ferric citrate, magnesium iron hydroxycarbonate, aluminum hydroxide, APS1585, SBR-759, and PA-21.

13. The method of claim 11 , wherein the phosphate binder is selected from the group consisting of sevelamer carbonate, lanthanum carbonate, calcium carbonate, calcium acetate, calcium acetate/magnesium carbonate, ferric citrate, magnesium iron hydroxycarbonate, and aluminum hydroxide.

14. The method of claim 11 , wherein the phosphate binder is sevelamer, sevelamer carbonate, or sevelamer hydrochloride.

15. The method of claim 3 , wherein the hyperphosphatemia is postprandial hyperphosphatemia.

Assignees

• Ardelyx Inc

Inventors

• Carreras Christopher
• Charmot Dominique
• Jacobs Jeffrey W
• Labonte Eric
• Lewis Jason G

Classifications

• A61P5/20

  for decreasing, blocking or antagonising the activity of PTH · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P3/12

  for electrolyte homeostasis · CPC title